Larimar Therapeutics Performance dei guadagni passati

Il passato criteri di controllo 0/6

Gli utili di Larimar Therapeutics sono diminuiti a un tasso annuo medio di -7.8%, mentre il settore Biotechs ha visto gli utili crescere a un tasso annuo di 7.7%.

Informazioni chiave

-7.8%

Tasso di crescita degli utili

36.3%

Tasso di crescita dell'EPS

Biotechs Crescita del settore	-14.6%
Tasso di crescita dei ricavi	n/a
Rendimento del capitale proprio	-32.6%
Margine netto	n/a
Ultimo aggiornamento sui guadagni	30 Sep 2024

Aggiornamenti sulle prestazioni recenti

Nessun aggiornamento

Recent updates

Ripartizione dei ricavi e delle spese

Come Larimar Therapeutics guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

DB:ZA71 Ricavi, spese e utili (USD Millions )
Data	Guadagni	Spese G+A	Spese di R&S
30 Sep 24	-65	17	57
30 Jun 24	-58	16	50
31 Mar 24	-45	15	36
31 Dec 23	-37	14	28
30 Sep 23	-33	14	24
30 Jun 23	-33	13	23
31 Mar 23	-33	12	23
31 Dec 22	-35	12	24
30 Sep 22	-35	12	23
30 Jun 22	-44	12	32
31 Mar 22	-47	12	35
31 Dec 21	-51	12	38
30 Sep 21	-56	13	43
30 Jun 21	-49	14	36
31 Mar 21	-48	13	35
31 Dec 20	-42	11	31
30 Sep 20	-34	9	26
30 Jun 20	-33	6	27
31 Mar 20	-25	4	22
31 Dec 19	-23	2	21

Guadagni di qualità: ZA71 al momento non è redditizia.

Margine di profitto in crescita: ZA71 al momento non è redditizia.

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: ZA71 non è redditizia e le perdite sono aumentate negli ultimi 5 anni a un tasso pari a 7.8% all'anno.

Accelerare la crescita: Impossibile confrontare la crescita degli utili di ZA71 nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia

Guadagni vs Settore: ZA71 non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Biotechs ( -18.2% ).

Rendimento del capitale proprio

ROE elevato: ZA71 ha un Return on Equity negativo ( -32.65% ), in quanto al momento non è redditizio.

Larimar Therapeutics Performance dei guadagni passati

Il passato criteri di controllo 0/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

Recent updates

Larimar Therapeutics, Inc. Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024

New major risk - Revenue and earnings growth

Larimar Therapeutics, Inc. Announces Data from the Nomlabofusp Phase 1 Studies and Phase 2 Dose Exploration Study

Larimar Therapeutics, Inc.(NasdaqGM:LRMR) dropped from Russell Small Cap Comp Value Index

United States Food and Drug Administration Selects Larimar Therapeutics, Inc. to Participate in Start Pilot Program for Nomlabofusp in Friedreich's Ataxia

Larimar Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Revenue and earnings growth

Larimar Therapeutics Announces the Dosing of the First Patient in Long-Term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’S Ataxia

New minor risk - Shareholder dilution

Larimar Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $150.000005 million.

Larimar Therapeutics, Inc. has withdrawn its Follow-on Equity Offering in the amount of $50 million.

Larimar Therapeutics, Inc. Reports Positive Top-Line Data from Phase 2 Dose Exploration Study from 25 Mg and 50 Mg Cohorts of Nomlabofusp in Patients with Friedreich's Ataxia

Larimar Therapeutics, Inc. Appoints Dr. Jeffery W. Sherman to its Board of Directors

Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601's Phase 2 Friedreich's Ataxia Trial

Larimar Therapeutics, Inc. Announces Chief Medical Officer Changes

Larimar Therapeutics Reports Preliminary Top-Line Data from Phase 2 Trial’S 25 Mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich’S Ataxia

Larimar Therapeutics, Inc. Appoints Gopi Shankar as Chief Development Officer

High number of new and inexperienced directors

CEO, President & Director recently bought €100k worth of stock

Larimar Therapeutics Announces FDA Clearance to Initiate the 25 mg Cohort of a Phase 2 Dose Exploration Trial of CTI-1601 in Friedreich’s Ataxia Patients

Larimar Therapeutics, Inc. Provides Updates on CTI-1601 Clinical Program Following A Type C Meeting with the U.S. Food and Drug Administration

High number of new and inexperienced directors

Larimar Therapeutics, Inc., Annual General Meeting, May 10, 2022

Larimar Therapeutics, Inc. Announces Not Stand for Re-Election of Thomas O. Daniel as Board of Director

Larimar Therapeutics, Inc. Provides Update on CTI-1601 Clinical Program

Independent Director recently bought €419k worth of stock

Larimar Therapeutics, Inc. Reports FDA Clinical Hold on CTI-1601

Larimar Therapeutics, Inc. announced that it expects to receive $95.273757 million in funding from Deerfield Management Company, L.P. and other investors

Larimar Therapeutics, Inc. Receives European Medicines Agency Priority Medicines (PRIME) Designation for CTI-1601 in Friedreich’s Ataxia

Larimar Therapeutics Reports Positive Topline Phase 1 Clinical Trial Data Showing Dose-Dependent Increases in Frataxin Levels in Patients with Friedreich’s Ataxia

New 90-day low: €15.00

Larimar Therapeutics Announces Completion of Dosing of the Single Ascending Dose Clinical Trial in Friedreich’s Ataxia Patients and Provides Program Update

New 90-day high: €18.90

New 90-day high: €18.50

New 90-day high: €15.42

Larimar Therapeutics Announces Formation of Scientific Advisory Board

New 90-day high - €13.82

Larimar Therapeutics, Inc.(NasdaqGM:LRMR) dropped from Russell Microcap Value Index

Ripartizione dei ricavi e delle spese

Storia dei guadagni e delle entrate

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Rendimento del capitale proprio

Rendimento delle attività

Rendimento del capitale investito

Scoprire le aziende con forti performance passate